Copyright: ©Author(s) 2026.
World J Diabetes. May 15, 2026; 17(5): 118754
Published online May 15, 2026. doi: 10.4239/wjd.v17.i5.118754
Published online May 15, 2026. doi: 10.4239/wjd.v17.i5.118754
Table 3 Interventional strategies for pancreatic macrophage metabolic memory
| Intervention strategy | Representative agents/methods | Mechanism of action | Specificity for memory erasure | Evidence type | Ref. |
| Lifestyle intervention | Aerobic exercise | Activates SIRT1 pathway, promotes macrophage M2 polarization, downregulates TNF-α/IL-6, upregulates IL-10 | High Rationale: > 8 weeks via H3K4me3/H3K27ac epigenetic remodeling; pancreatic macrophage direct evidence | Preclinical + clinical | [90,91] |
| Improves pancreatic macrophage metabolic reprogramming, enhances PKB2-mediated insulin signaling | Obese mice (n = 10/group): Reduces HOMA-IR, upregulates PBMC SIRT1 | ||||
| H3K27ac, inhibits HDAC3, modulates epigenetic memory | Obese humans (n = 89): Endurance exercise enhances insulin sensitivity | ||||
| Natural products | Resveratrol, curcumin | Resveratrol: Activates adenosine monophosphate - AMPK/SIRT1/Nrf2, inhibits NF-κB, enhances IL-10 promoter H3K27ac; regulates macrophage polarization (concentration-dependent) | Moderate Rationale: 2 weeks; histone modification; pancreatic macrophage direct evidence | Preclinical + clinical | [92,93] |
| Curcumin: Blocks TLR4/MyD88/NF-κB, inhibits NLRP3 inflammasome, reverses IL-6 promoter DNA methylation; alleviates pancreatic β-cell oxidative stress | Cells (3 independent experiments): Resveratrol reduces LPS-induced NO/TNF-α, curcumin inhibits IL-1β | ||||
| Human trial (n = 40): 1 g/day resveratrol increases SHBG, improves metabolism | |||||
| Epigenetic modulators | HDACi, miR-10a mimics | HDAC inhibitors: Inhibit HDAC1/2/3, reduce H3K27me3, activate Nrf2, enhance IL-10 expression | Extremely high Rationale: 4-8 weeks; reverses obesity-induced epigenetic abnormalities; pancreatic macrophage direct evidence | Preclinical + clinical | [94] |
| miR-10a mimics: Promotes pancreatic macrophage OXPHOS, increases acetyl-CoA/H3K18ac, inhibits HDAC3, modulates metabolic memory | Mice: Improves glucose/insulin resistance, reduces macrophage infiltration | ||||
| Lymphoma patients: MS-275 lowers TNF-α/IL-6 | |||||
| Human pancreatic macrophages: SAHA upregulates IL-10 | |||||
| miRNA-based intervention | miR-10a mimics, miR-146a mimics, miR-155 antagonists | miR-10a: Regulates metabolic reprogramming, enhances H3K18ac, blocks inflammatory memory | Extremely high Rationale: 6-8 weeks; reverses epigenetic abnormalities; pancreatic macrophage direct evidence | Preclinical | [91,95] |
| miR-146a: Targets HDAC2-PI3K axis, inhibits M1 polarization | Mice: MiR-10a reduces M1/M2 ratio, miR-146a improves insulin sensitivity | ||||
| miR-155 antagonists: Rescues PDX1, associated with pancreatic β-cell function | Cells: MiR-146a upregulates IL-10, miR-155 antagonists inhibit TNF-α | ||||
| Other | DMI | Mevalonate: Induces innate immune memory via inflammatory gene H3K27ac/H3K4me3 | Moderate Rationale: > 3 weeks; reverses partial inflammatory memory; pancreatic macrophage direct evidence | Preclinical | [91] |
| DMI: Enriches TNF/IL-6 promoter H3K4me3, reduces H3K9me3, regulates metabolic memory, inhibits inflammatory responses in pancreatic macrophages | Cells: Mevalonate enhances secondary inflammatory response, DMI inhibits LPS-induced TNF-α | ||||
| Animal experiment: DMI improves obesity-related inflammation |
- Citation: Wang YJ, Wang SY, Li ZM, Zhao MY, Zhou M, Xie CY, Wang JA, Xu B, Yang GH, Liu Y, Xu TC. Unlocking pancreatic metabolic memory: Can early interventions reverse obesity and block diabetes before it strikes? World J Diabetes 2026; 17(5): 118754
- URL: https://www.wjgnet.com/1948-9358/full/v17/i5/118754.htm
- DOI: https://dx.doi.org/10.4239/wjd.v17.i5.118754